Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest update is out from Aquestive Therapeutics ( (AQST) ).
Aquestive Therapeutics has provided a business update, highlighting its progress and strategic goals for 2025. The company is preparing to submit a New Drug Application for Anaphylm™, an epinephrine sublingual film, in early 2025, aiming for approval and market launch by the first quarter of 2026. Aquestive is also advancing its AQST-108 topical gel for alopecia areata, with a Phase 2a clinical trial scheduled for mid-2025. The company has received FDA approval for Libervant®, a buccal film for seizure clusters in young pediatric patients, and is focusing on expanding its market reach for these innovative treatments, suggesting an optimistic outlook for capturing market share in these therapeutic areas.
More about Aquestive Therapeutics
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on advancing medicines that bring significant improvements to patients’ lives through innovative science and delivery technologies. The company is committed to developing products that address critical unmet medical needs, with a strategic focus on the U.S. and international markets for its novel delivery systems, particularly in the realm of allergy management and epilepsy treatment.
YTD Price Performance: -16.08%
Average Trading Volume: 1,589,924
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $280.8M
For detailed information about AQST stock, go to TipRanks’ Stock Analysis page.
